Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
September 13, 2024 12:15 ET
|
Regeneron Pharmaceuticals, Inc.
Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNP Current treatment options leave many patients with uncontrolled disease and...
BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd.
September 13, 2024 12:05 ET
|
BioNexus Gene Lab Corp.
KUALA LUMPUR, Malaysia, Sept. 14, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC, the “Company”), an emerging biotechnology company focused on innovative healthcare solutions, is...
Mullen Automotive Inc. Announces Reverse Stock Split Effective Sept. 17, 2024
September 13, 2024 11:55 ET
|
Mullen Automotive, Inc.
BREA, Calif., Sept. 13, 2024 (GLOBE NEWSWIRE) -- via IBN -- Mullen Automotive Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an electric vehicle (“EV”) manufacturer, announced today that it will...
Télésat conclut des accords de financement de 2,54 milliards de dollars pour la constellation de satellites Télésat Lightspeed avec un soutien gouvernemental solide
September 13, 2024 11:10 ET
|
Télésat
MONTRÉAL, 13 sept. 2024 (GLOBE NEWSWIRE) -- Télésat (NASDAQ et TSX : TSAT), l'un des opérateurs de satellites les plus importants et les plus innovants au monde, a annoncé aujourd'hui la...
Telesat Completes $2.54 Billion Funding Agreements for Telesat Lightspeed Satellite Constellation with Strong Government Backing
September 13, 2024 11:10 ET
|
Telesat
MONTREAL, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Telesat (NASDAQ and TSX: TSAT), one of the world’s largest and most innovative satellite operators, today announced the completion of funding agreements...
Bitfarms Enters into 10,000 Miner Hosting Agreement with Stronghold Digital Mining
September 13, 2024 10:23 ET
|
Bitfarms Ltd.
- Agreement to support 2.2 EH/s with energization expected in October, two months ahead of schedule - - Company reiterates 2024 & 2025 guidance of 21 EH/s & 35+ EH/s, respectively - ...
VEON General Counsel Omiyinka Doris Named Among Top 15 Legal Leaders by the Financial Times
September 13, 2024 10:00 ET
|
VEON Ltd.
Amsterdam, 13 September 2024 – VEON Ltd. (Nasdaq: VEON, Euronext Amsterdam: VEON), a global digital operator that provides connectivity and online services, is delighted to announce that Omiyinka...
Jet.AI Opens New JetLeg.AI app to Beta Testers
September 13, 2024 10:00 ET
|
Jet.AI Inc.
LAS VEGAS, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Jet.AI Inc. ("Jet.AI" or the "Company") (NASDAQ: JTAI), an innovative private aviation and artificial intelligence company, invites users to beta test...
C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
September 13, 2024 10:00 ET
|
C4 Therapeutics, Inc.
CFT1946 Is Well-Tolerated at All Dose Levels; No Dose-Limiting Toxicities CFT1946 Achieves Dose Proportional Pharmacokinetic Exposure; Successfully Degrades BRAF V600 Mutant Protein ...
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
September 13, 2024 10:00 ET
|
Prelude Therapeutics, Incorporated
- Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer in early PRT3789...